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Parkinson’s disease (PD) is the most frequently occurring movement disorder, with an
increasing incidence due to an aging population. For many years, the post-mortem
brain was regarded as the gold standard for the analysis of the human pathology
of this disease. However, modern stem cell technologies, including the analysis of
patient-specific neurons and glial cells, have opened up new avenues for dissecting the
pathologic mechanisms of PD. Most data on morphological changes, such as cell death
or changes in neurite complexity, or functional deficits were acquired in 2D and few in 3D
models. This review will examine the prerequisites for human disease modeling in PD,
covering the generation of midbrain neurons, 3D organoid midbrain models, the selection
of controls including genetically engineered lines, and the study of cell-cell interactions.
We will present major disease phenotypes in human in vitro models of PD, focusing
on those phenotypes that have been detected in genetic and sporadic PD models. An
additional point covered in this review will be the use of induced pluripotent stem cell
(iPSC)-derived technologies to model cell-cell interactions in PD.
Keywords: Parkinson’s disease, iPSC, neurodegeneration, organoid, dopaminergic neuron, disease modeling,
inflammation, glia
INTRODUCTION PARKINSON’S DISEASE
Parkinson’s disease (PD) is the second most frequently occurring neurodegenerative disorder.
Clinically, PD patients suffer from motor symptoms, such as bradykinesia, rigor, and tremor, with
varying degrees of severity (Postuma et al., 2015). Neuropathological hallmarks of PD include the
selective loss of midbrain dopaminergic (mDA) neurons in the pars compacta of the substantia
nigra (SNpc), and the presence of α-synuclein-protein (α-Syn) in intracytoplasmic and intraneuritic
eosinophilic inclusions, termed Lewy bodies and Lewy neurites, respectively (Pakkenberg et al.,
1991; Braak and Braak, 2000). Around 90% of PD patients are diagnosed with sporadic PD, which
has a largely unknown etiology. In attempting to decipher this complex etiology, environmental
toxins such as heavy metals and pesticides, as well as psychostimulants, have gained increasing
attention, alongside multifactorial genetic processes (Ball et al., 2019). To date, the majority of
research has focused on familial PD, despite the fact that this constitutes less than 10% of all PD
cases. Pathogenic variants in genes including SNCA, LRRK2, PINK1, and PRKN2, as well as rare
mutations in e.g.,DJ-1,ATP13A2, PLA2G6, andGBA, have been identified as critical for this disease
(Singleton et al., 2013).
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The gold-standard treatment formotor symptoms in PD is the
pharmacological replacement of dopamine in the brain, either by
increasing dopamine concentrations or by stimulating dopamine
receptors (Connolly and Lang, 2014). In most PD cases,
dopaminergic (DA) therapy results in a significant amelioration
of motor symptoms, though this is merely symptomatic and
may lose efficiency over time (Kalia and Lang, 2015). Surgical
procedures, such as deep-brain stimulation, offer additional
symptomatic benefits and in particular have been reported to
improve on-off periods of motor symptoms observed at later
stages of the disease (Limousin et al., 1998; Castrioto et al., 2014).
However, no existing therapies target the neurodegenerative
process itself. Furthermore, it is becoming increasingly evident
that neuronal loss in PD does not arise solely from a neuron-
intrinsic degenerative mechanism, but is rather the result of a
complex process involving neurons and other CNS-resident and
non-resident cell types (Hirsch et al., 2013).
Due to difficulties in accessing patient brain tissue, the
majority of knowledge regarding PD pathology was originally
obtained from the study of postmortem brains (Baba et al.,
1998; Walker et al., 1998; Hunot et al., 1999). However, the
development of human stem cell-based technologies has
provided new possibilities for furthering our understanding
of PD pathophysiology and developing new therapeutic
strategies. Replacement strategies involving the transplantation
of dopamine-producing human stem cells into PD patients’
striatum have been implemented and are currently evaluated
by a worldwide consortium. Clinical studies are evaluating
the potential of this method to improve motor symptoms
while reducing or eliminating the need for DA medication
(Barker et al., 2015; Studer et al., 2019). Moreover, human
stem cell-based disease modeling provides a means of studying
both genetic and sporadic PD and also of testing for suitable
compounds that may target the neurodegenerative process
in PD (Marchetto et al., 2010; Durnaoglu et al., 2011). The
ongoing optimization of stem cell differentiation protocols for
the generation of various cell types and multicellular structures
paves the way for PD disease modeling in more complex
intercellular settings (Lancaster et al., 2013; Smits et al., 2019).
In this review article, we will first address the pre-requisites of
stem cell-based PD research: the efficient generation of relevant
models of functional mDA neurons in 2D and 3D settings. We
will then provide an overview of recent stem cell-based findings
in genetic and sporadic PD and describe both two- and three-
dimensional approaches to the disease modeling of various
cell-cell interactions.
HUMAN STEM CELL-DERIVED MODELS
FOR PD MODELING
Recent advances in stem cell biology have established
technologies to reprogram somatic cells to a state of pluripotency
comparable to human embryonic stem cells (hESCs). The
first reprogrammed cells termed induced pluripotent stem
cells (iPSCs), were generated by retroviral expression of
four transcription factors Oct3/4, Sox2, Klf4, and c-myc (or
alternatively Nanog) from adult fibroblasts jump-starting their
continuous expression (Takahashi et al., 2007). The resulting
possibility to differentiate these iPSCs further into neurons of
various neurotransmitter phenotypes opens new horizons for
the study of CNS diseases, where human brain tissue is otherwise
difficult to approach (Tao and Zhang, 2016). Alternative
resources for human disease models include ESCs derived from
the blastocyst, which are also able to generate a source for
brain cells.
Initial midbrain differentiation protocols mimicked
embryonic development by the formation of embryoid bodies or
the use of undefined co-culture systems (Kawasaki et al., 2000;
Perrier et al., 2004). The Studer lab later pioneered the conversion
of human pluripotent cells into a primitive neuroectoderm by
inhibiting the TGFβ/activin/nodal and BMP pathways, both
of which signal via SMAD2/3 and SMAD1/5 (Heldin et al.,
1997; Bond et al., 2012). This dual SMAD inhibition method was
further refined by adding sonic hedgehog (Shh) pathway agonists
for anterior floor plate identity and appropriately activating the
WNT signaling pathway [e.g., using the GSK3β inhibitor Chiron
(CHIR99021)] resulting in a majority of TH-positive floor plate
derived neurons (Chambers et al., 2009; Kriks et al., 2011).
In addition to the advances made in differentiating DA
neurons, the differentiation of other CNS resident cell types
from iPSCs and ESCs have made considerable progress in recent
years. Protocols for the differentiation of iPSC derived astrocytes
and microglia-like cells now enable disease modeling using
heterotopic 2D cell-cell interaction models (Abud et al., 2017;
di Domenico et al., 2019).
Given the complex etiology of PD, investigating the role of
spatial tissue organization, cell-cell- and cell-matrix connections
is likely to be crucial in determining new mechanisms in PD
pathogenesis. The possibility to differentiate stem cells into 3D
organ-like structures termed organoids now offers a variety of
opportunities to study neurodegenerative diseases (Kadoshima
et al., 2013; Lancaster et al., 2013). Specifically, the patterning
of organoid differentiation toward distinct brain-region specific
fates, includingmidbrain-like organoids containing DA neurons,
is of particular relevance in terms of PD (Qian et al., 2016;
Smits et al., 2019).
However, despite this astonishing progress, disease modeling
using human stem cells is still accompanied by a number of
caveats. Line-to-line variability is a prominent challenge in
identifying even subtle disease phenotypes in stem cell-derived
PD models. Consequently, genome editing techniques have
become highly important for the control of genetic variation as
they enable the introduction of a pathogenic mutation into a
control line (Soldner et al., 2016) or the correction of a mutation
in a patient line (Reinhardt et al., 2013b). The development of
CRISPR technology by Doudna and Charpentier (Jinek et al.,
2012) has thus greatly facilitated the generation of isogenic iPSC
lines, i.e., lines that have the same genetic background, differing
only in the mutation of interest.
An additional pitfall of iPSC and ESC derived model system
arises from the reprogramming process itself, which has been
shown to reset the epigenetic landscape of the derived cells into
a more embryonic-like state (Maherali et al., 2007; Guenther
et al., 2010). As aging constitutes one of the major risk factors for
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neurodegenerative diseases, it is not surprising that age-specific
epigenetic signatures emerge as potential additional drivers in
their pathogenesis (Hwang et al., 2017). Transdifferentiation
protocols, which allow the direct reprogramming of human
fibroblasts into neurons without an intermediate stem cell state,
has thus been pushed forward in order to preserve possible
patient-associated epigenetic changes (Ladewig et al., 2012;
Liu et al., 2013).
In summary, extremely productive efforts by the stem cell
field in recent years have greatly expanded the toolbox available
for PD disease modeling (see Figure 1). This toolbox has been
essential in identifying pathological phenotypes in human stem
cell models of familial and sporadic PD. In the next section,
we will provide an overview of the major phenotypes that were
recently identified.
MAJOR PHENOTYPES IN HUMAN iPSC
MODELS OF PD
Neurite Defects
Human iPSC technology offers a unique opportunity to analyze
specific neuronal structures, such as neurites, during maturation
and development of pathological features. Studies employing
these techniques have revealed abnormalities in iPSC-derived
neurons to be one of the most consistent features across different
neurodegenerative diseases. In PD pathology, changes in neurite
morphology have been associated with mutations in PARK2,
LRRK2, and SNCA (Ren et al., 2015; Lin et al., 2016; Kouroupi
et al., 2017; Korecka et al., 2019; see Figure 2).
In PARK2 iPSC derived neurons, decreased microtubule
stability affects neurite complexity. It was possible to rescue
neurite complexity by overexpressing parkin or by stabilizing
the microtubule network using microtubule-stabilizing
compounds. Long term culture of LRRK2G2019S mDA neurons
displayed decreased neurite length, as well as a number of
neurites per neuron, which is further exacerbated by the
treatment with 6-OHDA and Mg132 (Sánchez-Danés et al.,
2012; Lin et al., 2016). LRRK2G2019S mDA neurites are also
especially susceptible to decreases in Ca2+ influx, as chronic
treatment with thapsigargin resulted in neurite collapse
(Korecka et al., 2019). A decreased neurite outgrowth rate
in LRRK2G2019S patient-derived neurons was also reported
by Reinhardt et al. (2013b), who were able to restore
outgrowth velocities to the level of wild-type controls using
targeted gene correction. This phenotype was recapitulated
by introducing the G2019S mutation into the LRRK2 loci
of a control line. The impairment in neurite outgrowth
was also detectable after 5 days of differentiation. At this
differentiation stage LRRK2G2019S, immature neurons display
a shorter, but considerably more complex, neurite branching
(Borgs et al., 2016).
Mutations in LRRK2 also affect sensory neurons: while neurite
length and complexity of sensory neurons were not affected
by LRRK2 mutations, increased neurite swellings containing
cytoskeletal proteins, including tau and p-Tau, were present
(Schwab and Ebert, 2015).
In addition to neurite morphology, functional parameters
such as synaptic connectivity and axonal transport are impaired
in PD (Kouroupi et al., 2017; Prots et al., 2018). The proportion of
mobile mitochondria was reportedly increased in iPSC-derived
neurons from symptomatic and presymptomatic PD patients
carrying LRRK2G2019S and LRRK2R1441C mutations, respectively
(Cooper et al., 2012). Although the mechanism behind these
impairments remains elusive, the conformation, degree of
aggregation and phosphorylation of α-Syn evidently has a role
in the maintenance or formation of neurites (Qing et al., 2017;
Prots et al., 2018).
It is important to note that mutations inGBA and LRRK2 alter
the levels of SNCA (Woodard et al., 2014; Oliveira et al., 2015;
Lin et al., 2016). An interesting study carried out in monozygotic
twins harboring a heterozygous GBAmutation showed displaced
α-syn in the affected twin only, further suggesting that the
quantity of α-Syn and its distribution along the neurons play a
key role in neurite support (Woodard et al., 2014). The same
study also indicated that not only the genetic predisposition
but also additional factors contribute to the penetrance of PD.
In this regard, studies on sporadic PD cases are especially
valuable to shed light on which additional factors may alter
disease onset and progression. Different cohorts of iPSC derived
DA neurons from sporadic PD patients reported impairments
in neurite complexity; an autologous PD Lymphocyte/iPSC-
DA Neuron co-culture model for neuroinflammation, and
prolonged differentiation of 2D DA neuronal cultures (Sánchez-
Danés et al., 2012; Marrone et al., 2018; Sommer et al.,
2018). These studies showed stress-related decreased neurite
complexity in PD patients, suggesting that impairments in
morphology and neurite outgrowth might be a general feature
in PD pathology.
Aggregation
The pathological hallmarks of PD are Lewy bodies and Lewy
neurites, which are principally composed of aggregated α-Syn.
The importance of α-Syn is further emphasized by SNCA
mutations that have been shown to cause familial forms of
parkinsonism with early-onset and fast disease progression.
SNCA duplications or triplications and point mutations (A53T,
A30P, E46K) cause PD by increasing the gene dosage or
altering the biochemical properties of α-Syn (Kang et al.,
2011). iPSC-derived neurons generated from PD patients or
mutations introduced by CRISPR technology were able to model
α-Syn aggregation as the major pathological hallmark of the
disease (see Figure 2). Furthermore, iPSC derived models could
replicate important mechanisms of α-Syn aggregation, such as
oligomerization, phosphorylation, or secretion.
α-Syn accumulation has been demonstrated in iPSC derived
PD neurons of SNCA duplication (Prots et al., 2018), SNCA
triplication (Byers et al., 2011; Devine et al., 2011; Flierl et al.,
2014; Oliveira et al., 2015; Reyes et al., 2015; Heman-Ackah et al.,
2017; Vasquez et al., 2017) and point mutations in SNCA A53T
(Ryan et al., 2014; Kouroupi et al., 2017), LRKK2G2019S (Nguyen
et al., 2011; Reinhardt et al., 2013b), PARK2V324A (Imaizumi
et al., 2012; Chung et al., 2016), PINK1Q456X (Chung et al., 2016)
and GBAN370S (Woodard et al., 2014; Kim et al., 2018). A study
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FIGURE 1 | The growing induced pluripotent stem cell (iPSC) toolbox for Parkinson’s disease (PD) disease modeling.
FIGURE 2 | Major phenotypes observed in iPSC-derived dopaminergic (DA) neurons. The accumulation and aggregation of α-synuclein in PD models of iPSC
derived neurons was shown in the following publications: Byers et al. (2011), Devine et al. (2011), Nguyen et al. (2011), Imaizumi et al. (2012), Reinhardt et al.
(2013a), Ryan et al. (2013), Flierl et al. (2014), Woodard et al. (2014), Oliveira et al. (2015), Reyes et al. (2015), Chung et al. (2016), Mazzulli et al. (2016),
Heman-Ackah et al. (2017), Kouroupi et al. (2017), Vasquez et al. (2017), Kim et al. (2018), Ludtmann et al. (2018), Prots et al. (2018), Hu et al. (2019), Tagliafierro
et al. (2019) and Zambon et al. (2019). The phenotype of aberrant neurite morphology was described in Sánchez-Danés et al. (2012), Reinhardt et al. (2013b),
Woodard et al. (2014), Schwab and Ebert (2015), Borgs et al. (2016), Lin et al. (2016), Kouroupi et al. (2017), Sommer et al. (2018) and Korecka et al. (2019).
Increased cell death without additional stressors could be detected in Sánchez-Danés et al. (2012) and Bogetofte et al. (2019). Several publications detected
increased cell death rate in PD models of iPSC derived neurons adding additional stressors: Byers et al. (2011), Nguyen et al. (2011), Miller et al. (2013), Reinhardt
et al. (2013b), Flierl et al. (2014), Ryan et al. (2014), Shaltouki et al. (2015), Chung et al. (2016), Lin et al. (2016), Sommer et al. (2018).
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introducing a PD-associated risk variant in an isogenic iPSC line
using CRISPR technology was able to determine an enhancer
element that regulates α-Syn expression (Soldner et al., 2016).
The accumulation of insoluble α-Syn, expected to be part of
the aggregation cascade of α-Syn, was detected in a diverse set
of genetic PD models such as SNCA duplication (Prots et al.,
2018), SNCA triplication (Mazzulli et al., 2016; Ludtmann et al.,
2018; Tagliafierro et al., 2019) and the point mutations SNCAA53T
(Ryan et al., 2013; Kouroupi et al., 2017) PARK2V324A (Chung
et al., 2016), PINK1Q456X (Chung et al., 2016) and GBAN370S
(Kim et al., 2018). This reproduces aggregation as the shared
disease process of PD and underlines iPSC-derived models as
an adequate tool to investigate synucleinopathies on a cellular
level. The higher aggregation propensity of α-Syn was detected
by detergent-insoluble α-Syn (Chung et al., 2016; Mazzulli et al.,
2016; Kim et al., 2018; Prots et al., 2018), as well as Thioflavin
staining (Ryan et al., 2013; Kouroupi et al., 2017).
Together with the higher aggregation rate, changes such
as phosphorylation and oligomerization were recapitulated in
iPSC PD models. Increased Ser129-phosphorylation of α-Syn
could be detected in iPSC models of SNCA triplication (Lin
et al., 2016) SNCAA53T point mutation (Ryan et al., 2013;
Kouroupi et al., 2017; Hu et al., 2019) and the PARK2 mutation
(Ryan et al., 2013; Lin et al., 2016; Kouroupi et al., 2017).
Oligomers were previously shown to be a neurotoxic α-Syn
species (Winner et al., 2011). Multiple iPSC-derived SNCA
triplication models could show an increase in α-Syn oligomers
that were connected to axonal transport impairments (Prots
et al., 2018) and activation of the mitochondrial transition pore
(Ludtmann et al., 2018).
The main physiological α-Syn species remains controversial.
Studies detected a physiological tetrameric α-Syn species,
resistant to aggregation (Bartels et al., 2011; Wang et al., 2011;
Dettmer et al., 2015b). A SNCAA53T point mutation (Dettmer
et al., 2015a) and GBAN370S mutations (Kim et al., 2018)
were shown to disrupt this tetrameric form and increase the
monomeric α-Syn level in iPSC derived neurons.
Braak stated the hypothesis of spreading α-Syn pathology
with the course of the disease (Braak and Braak, 2000). One
route of α-Syn spreading is thought to be the secretion of α-
Syn into the extracellular space. IPSC-derivedmodels could show
increased extracellular levels of α-Syn in GBAN370S mutations
(Fernandes et al., 2016) and SNCA triplication cases (Zambon
et al., 2019). A recent study identified LRRK2G2019S astrocytes
as another source of α-Syn spreading to neurons (di Domenico
et al., 2019). This study stresses the flexibility of the iPSC models
to answer cell-type-specific questions, as co-cultures of control
astrocytes and LRRK2G2019S mutated neurons and vice versa
could give indications about the effect of certain cell types on
one another.
Recently, premature aging was introduced to iPSC models
of SNCA triplication by extended passaging at the NPC state.
These aged neurons showed a higher α-Syn aggregation rate
compared to the young SNCA triplication neurons (Tagliafierro
et al., 2019). The incorporation of aging adds an additional
layer of complexity that can be modeled by iPSC-derived PD
neurons. Thus, iPSC-derived models enable us to test hypotheses
about how PD-causing mutations affect α-Syn species and the
aggregation process.
Cell Death
Loss of DA neurons in the SNpc is another hallmark of PD.
The current hypothesis is that both genetic and environmental
factors contribute to PD-linked neuronal cell death (Ball et al.,
2019). This combinationmakes it challenging to study the disease
in vitro since the exposure to specific environmental factors
is usually difficult to trace back. PARK2 KO derived neurons
showed a decreased survival after 14 days of differentiation
compared to isogenic WT lines (Shaltouki et al., 2015) and
displayed higher levels of necrosis after 25 days (Bogetofte et al.,
2019). However, besides these studies, neuronal cell death is
rarely reported in iPSC-derived neuronal cultures without a
prior stressor challenge (see Figure 2). One of the best-studied
mutations in PD is the LRRK2G2019S. However, in the majority
of studies, no changes in cell viability were reported under
basal conditions. Sánchez-Danés et al. (2012) were able to find
increased cell death occurring in sporadic and familial cases
of LRRK2- related PD in vitro after prolonged differentiation.
This can be attributed to the increased maturity of the neuronal
culture. Longer neuronal cultures can also be achieved by
generating brain organoids. However, to date only two studies
have modeled PD using PD-patient derived midbrain organoids
(Kim et al., 2019; Smits et al., 2019) and cell death was reported
in only one of these (Kim et al., 2019).
One possible explanation for the lack of cell death in
iPSC-derived cultures under basal conditions may be the use of
well-adjusted cell culture media and supplements, which were
specially developed to support neuronal survival and counteract
oxidative stress. In addition, for neuronal differentiation, this
media is usually supplemented with additional neurotrophic
factors, including BDNF and GDNF (Björklund et al., 1997;
Zuccato and Cattaneo, 2009). Thus, this media combination
may mask some of the neurodegenerative phenotypes we wish
to model.
A second explanation for the lack of cell death may be
the loss of age-related markers, which inevitably occurs during
the process of reprogramming (Marion et al., 2009). These
age-related traits that are lost are not regained even in longer
in vitro maturation and consequently, these neurons still do
not faithfully mimic the age-related traits of an e.g., 50-year-
old PD patient neuron. Transdifferentiation might be an option
to retain age-related epigenetic traits for future experiments
(Mertens et al., 2015).
Despite these drawbacks, such neuronal cultures are especially
valuable when investigating early transcriptomic and proteomic
pathological changes, which may ultimately lead to activation
of apoptotic pathways. Transcriptomic analysis of SNCA
triplication in cortical neurons suggest that endoplasmatic
reticulum stress followed by activation of the IRE1a/XBP arm
of the unfolded protein response might be responsible for
cell death in PD (Heman-Ackah et al., 2017). Microarray
analysis of DA neurons derived from two patients with A53T
mutation in SNCA was associated with S-nitrosylation of
the anti-apoptotic transcription factor MEF2C contributing
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to mitochondrial dysfunction (Ryan et al., 2013). Moreover,
increase in oxidative stress and inflammation was associated with
induction of the necroptotic pathway in OPA-1 derived NPCs
(Iannielli et al., 2018). An autologous mDA-lymphocyte
co-culture suggested activation of the NFkB pathway, bringing
neuroinflammation into the spotlight (Sommer et al., 2018).
Finally, proteomic analysis of PARK2 KO iPSC-derived neurons
and isogenic lines used as controls identified dysregulation
of proteins involved in oxidative stress defense, mitochondria
respiration, cell cycle control and cell viability (Bogetofte et al.,
2019). Further, ‘‘omic’’ studies may shed some light on early-
associated PD-specific dysregulated pathways.
Stressor Response
A set of publications has been able to link cell death pathways
to dysregulated upstream cellular functions in PD patients’ cells.
These studies indicate a decrease in viability upon exposure
to stressors that challenge these dysregulated functions. An
example of these studies identifying and then challenging the
dysregulated pathway is published by Nguyen et al. (2011).
They first showed increased expression of genes involved in
oxidative stress response in iPSC-derived LRRK2G2019S patient
neurons. When adding the oxidative stressor H2O2, the patients’
derived DA neurons revealed a higher cell death rate (Wang
et al., 2011). Thus, this study demonstrated that iPSC models
are a powerful tool to study the environmental component
in vitro. As previously mentioned, both environmental and
genetic factors contribute to the current hypothesis of PD
pathogenesis. Oxidative stress, mitochondrial dysfunction,
proteasome inhibition, and aging factors have all been identified
as playing a role in PD. The following four paragraphs describe
publications that have combined these factors with genetic
iPSC PD models.
Mitochondrial dysfunction is a core pathomechanism of
PD (Franco-Iborra et al., 2018). This is underlined by the
environmental risk factor rotenone, which inhibits the complex
I of the mitochondrial electron transport chain and is
epidemiologically linked to PD (Tanner et al., 2011). Another
mitochondrial stressor inhibiting mitochondrial complex I,
MPTP, also causes PD symptoms within days of exposure
(Langston, 2017). An increased susceptibility towards rotenone
(Cooper et al., 2012; Ryan et al., 2013; Flierl et al., 2014;
Mittal et al., 2017; Tabata et al., 2018) and MPTP (Kim et al.,
2019) was also determined in neurons and organoids from
iPSC-derived PD patients’. Carbonyl cyanide m-chlorophenyl
hydrazine (CCCP) decreases the mitochondrial membrane
potential and PINK1 and PARK2 iPSC-derived DA neurons
were more prone to cell death after treatment with CCCP
(Chung et al., 2016).
Oxidative stress is one of the major biochemical processes
thought to impair the vulnerability of DA neurons in PD.
Pesticides and heavy metals (Tanner et al., 2011; Farina et al.,
2013), as well as PD-causing mutations (e.g., PARK2, PINK1,
SNCA, LRRK2; Blesa et al., 2015), have been shown to induce
oxidative stress. Several factors known to induce oxidative stress
are used in iPSC PD studies, such as the pesticide paraquat, the
synthetic dopamine analog 6-hydroxydopamine (6-OHDA) and
the reactive oxygen species H2O2. Paraquat is epidemiologically
linked to PD (Tanner et al., 2011) and increased susceptibility
to this pesticide could be determined in iPSC PD neurons (Ryan
et al., 2013; Lin et al., 2016). 6-OHDA is a synthetic neurotoxin,
taken up via the dopamine transporter and selectively damaging
DA neurons due to ROS generation (Hernandez-Baltazar et al.,
2017). An increased vulnerability of PD patients’ derived neurons
towards 6-OHDA has been determined (Nguyen et al., 2011;
Lin et al., 2016). Adding the reactive oxygen species H2O2 to
LRRK2G2019S (Nguyen et al., 2011), LRRK2I2020T (Ohta et al.,
2015) or SNCA triplication neurons (Byers et al., 2011), revealed
a higher vulnerability of cells carrying PD-causing mutations
towards oxidative stress. There is evidence linking heavy metal
exposure to the development of PD, thought to be at least
partly due to the generation of oxidative stress (Ball et al.,
2019). An increased susceptibility towards the heavy metals
copper (Aboud et al., 2015), cadmium (Aboud et al., 2015), and
manganese (Aboud et al., 2012) were determined in iPSC-derived
PD patients’ neurons.
The proteasome system, which plays a central role in
degrading dysfunctional proteins, has been shown to be
impaired in the postmortem substantia nigra (SN) of PD
patients (Bentea et al., 2017). Exposure to the proteasomal
inhibitor carbobenzoxyl-L-leucyl-L-leucyl-L-leucine (MG-132)
determined a higher susceptibility in PD patients’ cells (Nguyen
et al., 2011; Lin et al., 2016).
Aging is a major risk factor for PD. Reprogramming has
been shown to rejuvenate the cells by resetting aging markers,
e.g., mitochondrial ROS, nuclear morphology markers and DNA
damage markers (Miller et al., 2013). Aging is known to drive
major pathomechanisms of PD, e.g., mitochondrial and oxidative
stress (Rodriguez et al., 2015). The addition of aging factors
can provide a way of determining higher susceptibility within
iPSC models of genetic PD that is compensated for during
the rejuvenation in the iPSC model. Studies have so far added
a variety of aging factors together with different PD-causing
mutations, all of which resulted in a higher susceptibility. Several
strategies have been applied to induce premature aging, e.g.,
telomerase inhibition (Vera et al., 2016), progerin expression
(Miller et al., 2013) and higher NPC passaging (Tagliafierro
et al., 2019). The susceptibility towards the aging factors was not
specific to a certain mutation, as shown for PARK2V324A (Miller
et al., 2013) PINK1Q456X (Miller et al., 2013; Vera et al., 2016)
and SNCA triplication cases (Miller et al., 2013; Vera et al., 2016;
Oh, 2019).
IPSC technology and epidemiology can both provide valuable
insights into Parkinson disease. The addition of environmental
risk factors to iPSC-derived models generates PD models that
can investigate the combinatorial effects of genes and the
environment. This allows a deeper insight into the interactions
and dependencies between the affected cellular processes critical
to the cell to maintain homeostasis. This can help to determine
the key cellular pathways challenged by multiple exposures
occurring over a lifetime, recently summarized by the concept
of the ‘‘neuroexposome.’’ These combinatorial effects may be of
particular significance when investigating genetic risk factors e.g.,
SNPs identified in genome-wide association (GWAS) studies.
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While genetic risk factors increase the risk for developing PD,
they are not causative and depend on the presence of other
risk factors, including environmental factors. This interplay of
genetic risk factors that render DA neurons more susceptible
to environmental factors takes place in sporadic PD. Indeed,
our lab was able to identify an increased vulnerability of iPSC-
derived, sporadic PD patients’ neurons towards interleukin 17.
The cell death rate of sporadic PD patients’ cells was equal
to cells from healthy individuals in unstressed conditions, but
significantly higher when exposed to IL-17 secreting T helper
17 cells (Sommer et al., 2018).
Neurodegenerative phenotypes in PD patients’ neurons
become more evident with the addition of cellular stressors.
Yet the comparability of different studies remains problematic,
as differentiation protocols, maturation time as well as stressor
dosage and duration tend to vary between different studies.
MODELING CELL-CELL INTERACTIONS IN
PD USING HUMAN iPSC-DERIVED
MODELS
As mentioned above, mounting evidence indicates that
neurodegeneration in PD is not a neuron-autonomous process,
but rather the result of a complex detrimental interplay between
a variety of different cell types (Hirsch et al., 2013). Recent
advances in the differentiation of human iPSCs and ESCs
have now expanded the toolbox available for studying PD via
2D co-culture models as well as 3D organoid models. In the
following section, we discuss recent findings of studies using
these models, highlighting specific cell-cell interactions as well
as organoid models. Moreover, we also address new possibilities
for future investigations of cell-cell interactions in PD.
Neuron—Astrocyte
Although the majority of existing studies on PD aimed to
investigate neuronal function, there is now increasing evidence
that astrocytes play an important role in PD pathogenesis. Recent
transcriptomic analyses using human and rodent CNS-resident
cells have shown that a variety of PD associated genes are
expressed in human astrocytes to a similar, and sometimes
even larger extent, compared to neurons (Zhang et al., 2016).
Astrocyte-specific functions have been identified for a variety
of genes known to be causative for PD, including DJ-1,
SNCA, PARK1, PARK2, PARK7, PLA2G6, and ATP13A2. These
functions include regulation of astrocyte neurotrophic properties
and their response to inflammatory stimuli, as well as astrocytic
glutamate transport and mitochondrial function (reviewed
extensively in Booth et al., 2017). Most of these studies were
conducted in both rodent models and in post-mortem human
brain tissue. While stem-cell-derived technologies now open up
many possibilities to study astrocyte function in a human system
(Krencik and Zhang, 2011; Roybon et al., 2013; Santos et al., 2017;
Tcw et al., 2017; Perriot et al., 2018), studies on astrocyte function
in PD using iPSC- or ES-derived cellular systems remain scarce.
Using a co-culture system of iPSC-derived neural progenitor
cells and astrocytes, astrocytes exerted a protective effect.
Interestingly, while treatment with mitochondrial stressors
rotenone and potassium cyanide led to a significant decrease in
NPC maturation into DA neurons, co-culture with iPSC-derived
astrocytes rescued differentiation deficits and mitochondrial
dysfunction in iPSC-derived DA neurons (Du et al., 2018).
These results clearly highlight the important role of astrocytes
in regulating mitochondrial homeostasis of DA neurons under
stress conditions. However, it has yet to be determined how
this protective effect during differentiation may be translated
into a PD disease context, given the fact that neurodegeneration
in PD sets in after maturation of DA neurons. Moreover,
it is not clear whether PD-causing pathogenic variants may
lead to a disturbance of these protective astrocyte functions
during differentiation.
A recent study by di Domenico et al. (2019) made use of
a neuron-astrocyte co-culture approach to study the effect of
a PD-causing LRRK2 mutation on neuron-astrocyte crosstalk
(G2019S). Remarkably, the co-culture of control iPSC-derived
mDA neurons with patient-derived astrocytes harboring
the LRRK2 G2019S mutation exerted a neurodegenerative
phenotype, while co-culture with control astrocytes did not
result in this effect. The neurodegenerative phenotype was
characterized by decreased cell survival and morphological
alterations in mDA neurons, as well as an accumulation of
α-Syn in mDA neurons and mutant astrocytes. Activation of
chaperone-mediated autophagy was, at least in part, able to
rescue these effects (di Domenico et al., 2019).
These results emphasize the dual role astrocytes may
play during PD pathogenesis. On the one hand, the loss
of astrocytic neurotrophic and neuroprotective properties
might be an important driver of PD pathogenesis. On
the other hand, astrocytes could gain neurotoxic abilities
upon progression of the disease and may themselves release
neurotoxic factors. As an inadequate response and higher
vulnerability to environmental stressors are possible causes
for sporadic PD, modeling sporadic PD via neuron-astrocyte
interactions upon different stressor conditions may be of
particular interest. Interestingly, recent studies showed that PD
patient brain samples harbor an increased number of senescent
astrocytes (Chinta et al., 2018). Whether these senescent
astrocytes contribute to neurodegeneration via the loss of their
neuroprotective function or the release of neurotoxic factors
remains to be elucidated. Stem-cell derived co-culture systems
may provide a valuable platform in deciphering the role of
these astrocytes in PD pathogenesis. However, it may be difficult
to model the late-stage effects of an aberrant astrocyte-neuron
interaction in PD using iPS derived 2D co-culture approaches
due to the fetal identity of iPS derived neurons and astrocytes.
The addition of stressors inducing aging effects may thus be
needed in the co-culture set up in order to gain insights
into the contribution of astrocytes to later time points of
PD pathogenesis.
Neuron—Immune Cells
Microglia represent the resident macrophage population in
the central nervous system (CNS). In response to a variety
of disease-associated stimuli, including microbes or even
unfolded and aggregated proteins like α-Syn oligomers
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and fibrils, microglia can become activated and initiate an
inflammatory response in CNS (Wolf et al., 2017). Several
studies have provided direct evidence for a microglia-mediated
inflammatory response in neurodegenerative diseases including
PD (reviewed in Song and Colonna, 2018). In post-mortem
studies of PD patient brains, as well as in living patients,
microglia activation has been demonstrated (Hirsch et al., 2003;
McGeer and McGeer, 2008). Interestingly, epidemiological
studies were able to show that the risk of PD is reduced in
patients receiving long-term treatment with certain nonsteroidal
anti-inflammatory medications, supporting the idea that
inflammatory pathways contribute to PD progression (Bartels
et al., 2010; Rees et al., 2011). Until now, the vast majority
of studies on microglial function in health and disease have
relied on rodent models. As recent studies indicated major
transcriptomic differences between human and rodent microglia
(Butovsky et al., 2014; Gosselin et al., 2017), the investigation
of microglial function in a human system is urgently required
to delineate the mechanisms and functional consequences of
microglia activation in human neurodegenerative diseases.
Protocols generating microglia-like cells (iMGLs) from
iPSCs may provide a valuable resource in characterizing
human microglial function. As microglia originate from
hematopoietic stem cells of the yolk sac (Ginhoux et al., 2010),
microglia differentiation differs extensively from differentiation
procedures of neuroectoderm-derived cells such as neurons,
oligodendrocytes, and astrocytes. Muffat et al. (2016) were the
first to report a protocol for microglia differentiation based on
the induction of cystic embryoid bodies resembling yolk-sac-like
cells and subsequent maturation with colony-stimulating factor
1 and IL-34. A feeder and serum-free differentiation method,
which exhibited good scalability and high purity were first
described by Abud et al. (2017). They made use a two-step
differentiation in which iPSCs were first differentiated into
hematopoietic stem/progenitor cells (HSPCs) and afterward
matured into iMGLs.
Thus far, existing literature delineating the role of microglia
in neurodegenerative diseases using iMGLs remains sparse.
Nevertheless, a number of studies in other neurodegenerative
diseases point toward the possible impact of iMGLs. A study
by Lin et al. (2016) showed morphological alterations and
a reduced capacity of extracellular amyloid-beta clearance
in iPSC-derived microglia-like cells carrying the ApoE4 risk
variant for Alzheimer’s disease compared to controls. Using
iPSC cells from patients carrying a disease-causing variant of
the TREM2 protein, another study was able to show that
TREM2 deficient microglia show specific deficits in phagocytosis
of apoptotic cells (Garcia-Reitboeck et al., 2018). Like astrocytes,
microglia may play a dual role in PD pathophysiology by
exerting both a protective and detrimental effect dependent on
the disease-state.
A number of different concepts and hypotheses for the
role of microglia in neurodegeneration have been developed
in an effort to summarize the existing data. The concept
of ‘‘microglia-priming’’ assumes that microglia exhibit
an inherently aberrant response to disease-associated
proinflammatory stimuli in neurodegeneration—potentially
initiating and exacerbating the course of the disease (Perry and
Holmes, 2014). Another possibility is that microglia respond
adequately to neuroinflammatory stimuli before disease onset,
but then undergo a phenotypic switch towards detrimental
‘‘degeneration-associated-microglia’’ as a result of accumulating
inflammatory stimuli and aging effects (Song and Colonna,
2018). An investigation of the human microglia response to
different PD associated stimuli may shed light on these different
concepts in Parkinson disease. However, it has to be taken into
account that microglial identity and function strongly relies
on the presence of paracrine and juxtacrine cues provided by
surrounding cells of the CNS including neurons (Abud et al.,
2017; Gosselin et al., 2017; Hasselmann et al., 2019). Thus,
a co-culture of iMGLs with iPSC-derived mDA neurons, in
particular, may represent a valuable system in deciphering
the effect of microglia on DA neurons under steady-state and
stress conditions in a more physiological environment. As
iMGLs and iPSC-derived mDA neurons have been shown
to more closely resemble their fetal cellular counterparts, an
iMGL-mDA neuron co-culture may be of specific value for
the investigation of a possible ‘‘primed microglia’’ phenotype.
Nevertheless, more sophisticated 2D co-culture systems also
including other glial cells as transducers or even more complex
3D culture systems may be needed to more closely model
in vivo human microglial function in a PD disease context (see
‘‘Organoids’’ section).
The concept of neuroinflammation in PD has long been
principally attributed to innate immune cells of the CNS,
like microglia (Muffat et al., 2016). However, studies that
demonstrated the activation of T lymphocytes by α-Syn, as well
as T-cell subset alterations in blood samples of PD patients,
raised the possibility of a peripheral immunity involvement in PD
pathogenesis (Baba et al., 2005; Stevens et al., 2012; Sulzer et al.,
2017). Animal models have provided some functional evidence
for a T-lymphocyte involvement in PD pathology (Brochard
et al., 2009; Reynolds et al., 2010; Sommer et al., 2016). In
addition, a recent study by Sommer et al. (2018) made use of
a co-culture system between T-lymphocytes and iPSC-derived
midbrain neurons to enumerate the role of T-cells in sporadic
PD. Strikingly, the autologous co-culture of patient midbrain
neurons with patient IL-17 producing T-cells leads to increased
cell death in neurons compared to a non-autologous co-culture.
This effect was dependent on IL-17 receptor signaling, as
blockage of IL-17 or IL-17 receptor rescued neuronal death
(Sommer et al., 2018). These results emphasize the possible role
of adaptive immune cells in PD pathogenesis. Adding microglia
to a co-culture system of T-cells and neurons may thus provide
a means of determining how the interplay between adaptive and
innate immunity shapes PD pathogenesis.
Organoids
Generation of human iPSC-derived DA neurons from PD
patients could recapitulate certain disease phenotypes such
as neurite pathology or neuronal cell death. Although the
co-culture of DA neurons and different cell types such as
astrocytes or microglia may bring the in vitro model closer
to the in vivo situation, the complex organization of the
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FIGURE 3 | Cell-cell interactions in the pathogenesis of PD—recent advances using iPSC-derived disease modeling. Opaque arrows depict recent findings made
using iPSC-derived cell-cell interaction models; pale arrows show mechanisms that still need investigation via iPSC-derived human disease modeling.
human brain remains a major challenge. One of the difficulties
in modeling late-onset neurodegenerative diseases like PD is
the immaturity of human iPSC-derived DA neurons in vitro.
Moreover, current 2D culture systems lack cell-cell interactions
of neurons and non-neuronal cells such as glia cells in a spatially
organized environment.
Recent advances in the generation of 3D cell culture systems,
so-called organoids, open up new possibilities for iPSC-based
disease modeling of PD. Differentiation protocols for human
brain organoids make use of the intrinsic self-organization
capability of pluripotent stem cells. Aggregation of single-cell
iPSCs into embryoid bodies mimics the organization of the
three germ layers during embryonic development. Culturing
in minimal medium enables the differentiation of the outer
layer to ectodermal fate. Embedding of these structures
in extracellular matrices leads to a further outgrowth of
neuroepithelium by serving as a supporting scaffold and
induction of the apical-basal polarity as it is seen for the
neural tube during embryonic neurodevelopment. Consequently,
brain-region specific organoids offer enormous possibilities for
long-term disease modeling of human neurodegeneration in
specialized brain regions, such as the SN in PD.
Similar to the 2D differentiation of human iPSC-derived DA
neurons, human midbrain organoids (hMOs) containing DA
neurons are generated by patterning of iPSCs to midbrain fate.
Either human iPSCs (Jo et al., 2016; Qian et al., 2016; Kim
et al., 2019) or already patterned neural stem cells (Monzel
et al., 2017; Smits et al., 2019) are aggregated as single cells
to form hMOs.
Midbrain specific differentiation approaches led to radially
organized midbrain organoids consisting of a proliferative
ventral zone, an intermediate zone, and an outer neuronal layer.
After around 2 months, the hMOs express the respective
midbrain markers (e.g., FOXA2, dopamine transporter
DAT) and contain 54%–65% TH-positive DA neurons.
Electrophysiological analysis by whole-cell patch clamping and
multielectrode arrays (MEA) revealed functional neurons and
synchronized neuronal networks. Moreover, the accumulation
of neuromelanin, a byproduct of dopamine metabolism in
2 months old hMOs, represents an intriguing line of inquiry for
disease modeling.
To date, only two studies describe disease modeling of PD
using hMOs (Kim et al., 2019; Smits et al., 2019). In both
cases, the focus was on a specific LRRK2 mutation (G2019S).
LRRK2G2019S hMOs have deficits as indicated by a decreased
number of TH-positive neurons and a reduction of neuronal
complexity. In addition, increased MPTP-induced cell death of
DA neurons in mutant organoids and abnormal localization of
phosphorylated α-Syn was present. Inhibition of LRRK2 kinase
activity resulted in a reduction of DA cell death and a reduction
of phosphorylated α-Syn.
These results indicate that hMOs can indeed recapitulate
aspects of PD pathology that have been already shown in
2D models. However, human brain organoids lack some glial
cell types like oligodendrocytes or microglia (Quadrato et al.,
2017; Sloan et al., 2017). As a result, co-culture models of
midbrain organoids and non-neuronal cell types are required.
Recent transcriptomic studies on human microglia were able to
determine that their transcriptional identity is heavily dependent
on intercellular, three-dimensional cues (Gosselin et al., 2017).
It will be challenging to establish applicable 3D co-culture
models due to the appropriate timing of differentiation and
media compositions to introduce one or more additional cell
types into the organoids. Moreover, activation of apoptosis
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within larger organoids due to lack of oxygen and nutrients
(Mansour et al., 2018) might interfere with PD models focusing
on oxidative stress.
It is suspected that the leakiness of the blood-brain-barrier
(BBB)may lead to the observed infiltration of peripheral immune
cells (Sommer et al., 2018). Consequently, 3D culture conditions
need to be further optimized for the co-culture of hMOs and, for
example, patient-derived blood lymphocytes. Nonetheless, one
needs to consider that stem cell-based models still resemble fetal
stages of neurodevelopment and that even premature aging using
substances like progerin creates an artificial model of age-related
phenotypes as seen in PD.
OUTLOOK
Since the first report describing successful reprogramming
of human fibroblasts into iPSCs over a decade ago, recent
progress has underscored the importance of iPSCs as a powerful
tool to model neurodegenerative diseases, including PD, in a
human system. As a pre-requisite, various iPSC-differentiation
protocols now enable the generation of DA neurons,
astrocytes, and microglia as well as complex three-dimensional
neuronal structures, termed organoids. Future innovation and
optimization of differentiation protocols should be able to
accelerate research progress in this field even further.
It should be noted that while studies on iPSC-derived
midbrain dopaminergic (mDA) neurons in isolated culture
systems were able to recapitulate major pathological hallmarks
of PD, including neurite defects and aggregation of α-Syn, they
found very little cell death. The addition of further stressors
appears to be an essential step in observing cell death in
iPSC-derivedmodel systems of PD (see Figure 2). These stressors
have been shown to include toxins, aging effects and the addition
of other cell types to the culture system.Major reasons for limited
pathology in PDmodels are that cultivation media are optimized
to prevent neurodegeneration, the iPSC derived neural models
mimic a fetal developmental stage and thatmajor epigenetic traits
are lost during reprogramming. Given the complex etiology of
the neurodegenerative process in PD, co-culture approaches of
different neural cell types provide unique opportunities for future
disease modeling (depicted in Figure 3).
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